Drug Trial Radar · NCT06466785
A Phase 3 Study of Efepoetin Alfa for Treatment of Anemia in Patients With Chronic Kidney Disease on Dialysis
Last checked: Nov 19, 2026Latest source record: May 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
429
Planned (sponsor's estimate)
Start
Jan 25, 2024
Primary completion
Jun 2027
Study completion Mar 2028
Sponsor
- Lead sponsor
- Genexine, Inc.Industry
- Sponsor type
- Industry
- Collaborators
- PT Kalbe Genexine Biologics
- First posted
- Jun 20, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
An investigator-blinded, randomized, multicenter, active-controlled Phase III study for the treatment of anemia in patients with CKD on hemodialysis
Conditions
- Anemia of Chronic Kidney Disease
Interventions
Efepoetin AlfaDrug
Efepoetin alfa (Epoetin-Fc fusion protein, GX-E2 or GX-E4,) is a novel long-acting erythropoietin-hybrid fragment crystallizable (Fc) fusion protein developed by Genexine, intended for treatment and maintenance of anemia due to CKD with or without dialysis. Its drug substance is a recombinant form of human EPO and hybrid Fc (hyFc®) fragment consisting of 2 subunits with a total of 411 amino acid residues. Each subunit contains an EPO molecule linked to a hybrid Fc fragment of c terminal of CH2 and CH3 regions from IgG4 and to N-terminal of CH2 region and the hinge sequence from IgD. These 2 subunits are joined by a single disulfide bond at the hinge region of each subunit. Half-life is 138.5-157.9 hours. It is an acidic glycoprotein of about 30 kDa and comprises 165 amino acids and 4 glycans. Circulating EPO exhibits several glycosylation isoforms that differ in electrical charge and biological activity
Darbepoetin AlfaDrug
Darbepoetin alfa is a re-engineered form of erythropoietin containing 5 amino acid changes (N30, T32, V87, N88, T90) resulting in the creation of 2 new sites for N-linked carbohydrate addition. It has a 3-fold longer serum half-life compared to epoetin alpha and epoetin beta. It stimulates erythropoiesis (increases red blood cell levels) by the same mechanism as rHuEpo (binding and activating the Epo receptor) and is used to treat anemia, commonly associated with chronic kidney failure and cancer chemotherapy
Primary outcomes
What the sponsor says the trial is designed to measure.
- Mean change in hemoglobin (Hb)Time frame: Over Week 20 to Week 28
Locations
58 sites in 11 countries. Site status is shown where the registry gives one.
"ARABKIR" Joint Medical Center & Institute of Child and Adolescent Health
Yerevan, Armenia · Recruiting
"BEST LIFE" Medical Center Armenian-Japanese Joint Venture LLC
Yerevan, Armenia · Recruiting
'Astghik'' Medical Center
Yerevan, Armenia · Recruiting
Multiprofile Hospital for Active Treatment Puls AD
Blagoevgrad, Bulgaria · Recruiting
Department of Dialysis Treatment, Multiprofile Hospital for Active Treatment - Dobrich AD, Dobrich
Dobrich, Bulgaria · Recruiting
Department of Nephrology, Dialysis Treatment, Multiprofile Hospital for Active Treatment "Dr. Tota Venkova" AD, Gabrovo
Gabrovo, Bulgaria · Recruiting
First Dialysis Services Bulgaria EAD, branck Montana
Montana, Bulgaria · Recruiting
Diaslys Center - Pazardzhik
Pazardzhik, Bulgaria · Recruiting
Department of Dialysis Treatment, Multiprofile Hospital for Active Treatment - Plovdiv AD, Plovdiv
Plovdiv, Bulgaria · Recruiting
First Dialysis Services Bulgaria EAD, Plovdiv
Plovdiv, Bulgaria · Recruiting
Department of Dialysis Treatment, University Multiprofile Hospital for Active Treatment "Medica Ruse" OOD, Ruse
Rousse, Bulgaria · Recruiting
Department of Dialysis Treatment, Multiprofile Hospital for Active Treatment "Dr. Ivan Selimski - Sliven" AD, Sliven
Sliven, Bulgaria · Recruiting
Acibadem CityClinic UMHAT Tokuda EAD
Sofia, Bulgaria · Recruiting
Dialysis Center - Dialmed
Sofia, Bulgaria · Recruiting
Dialysis Center Hemomed EOOD
Sofia, Bulgaria · Recruiting
Multiprofile Hospital for Active Treatment Sveta Anna - Varna AD
Varna, Bulgaria · Recruiting
Nemocnice Cesky krumlov
Český Krumlov, Czechia · Recruiting
Nemocnice Havlíčkův Brod
Havlíčkův Brod, Czechia · Recruiting
HDS Privamed Healthia sro v Plzni
Pilsen, Czechia · Recruiting
B. Braun Avitum s.r.o - Dialyzacni stredisko Teplice - Nefrologicka ambulance
Teplice, Czechia · Recruiting
Batumi Dialysis and Nephrology Center
Batumi, Georgia · Completed
Clinical Center for Nephrology Development
Tbilisi, Georgia · Completed
L.Managadze National Center of Urology
Tbilisi, Georgia · Completed
Tbilisi Heart And Vascular Clinic
Tbilisi, Georgia · Completed
RSUP Dr. Hasan Sadikin
Bandung, Indonesia · Completed
RS Islam Jakarta Cempaka Putih
Jakarta, Indonesia · Completed
RSPAD Gatot Soebroto
Jakarta, Indonesia · Completed
RSUPN Dr. Cipto Mangunkusumo
Jakarta, Indonesia · Completed
Azienda Socio Sanitaria Territoriale (ASST) degli Spedali Civili di Brescia- Unità Operativa (UO) Nefrologia
Brescia, Italy · Recruiting
SODc Nefrologia Dialisi Trapianto Azienda Ospedaliero Universitaria Careggi
Florence, Italy · Recruiting
"Azienda Ospedaliero Universitaria ""Ospedali Riuniti"" di Foggia Unità Operativa Complessa di Nefrologia, Dialisi e Trapianto"
Foggia, Italy · Recruiting
IRCCS Ospedale Policlinico San Martino
Genova, Italy · Recruiting
ICS Maugeri
Pavia, Italy · Recruiting
AOU Pisana UO Nefrologia Trapianti e Dialisi
Pisa, Italy · Recruiting
AOU Integrata di Verona UOC Nefrologia
Verona, Italy · Recruiting
Wojewodzki Szpital Specjalistyczny im. Kazimierza Dluskiego w Bialymstoku
Bialystok, Poland · Recruiting
DaVita Stacja Dializ Brodnica
Brodnica, Poland · Recruiting
Samodzielny Publiczny Zakład Opieki Zdrowotnej Centralny Szpital Kliniczny Uniwersytetu Medycznego w Łodzi
Lodz, Poland · Recruiting
DaVita Sp. z o.o. Pszczyna
Pszczyna, Poland · Recruiting
DaVita Stacja Dializ WADOWICE
Wadowice, Poland · Recruiting
Showing 40 of 58 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.